📊 CCM Key Takeaways
Is Concord Medical Services Holdings Ltd (CCM) a Good Investment?
Unable to conduct meaningful fundamental analysis due to unavailable financial data across all key metrics. The company appears to have significant data reporting gaps that prevent assessment of profitability, financial health, cash flow generation, or operational performance.
Concord Medical's fundamentals are weak: 2024 revenue fell 28.5% to RMB384.0 million while net loss widened to RMB652.1 million and operating cash outflow worsened to RMB397.7 million. The balance sheet is heavily stressed, with net current liabilities of RMB1.14 billion, total borrowings above RMB3.7 billion at year-end 2024, and a shareholders' deficit at the parent level. First-half 2025 showed better gross loss and a much smaller loss attributable to shareholders, but the company still appears dependent on external financing rather than internally generated cash.
Why Buy Concord Medical Services Holdings Ltd Stock? CCM Key Strengths
- No strengths identified
- First-half 2025 showed meaningful operating improvement, with gross loss narrowing sharply and loss attributable to shareholders falling versus the prior-year period
- The company has a sizable asset base centered on hospitals and oncology infrastructure, which could support long-term strategic value if utilization improves
- It has continued access to financing, including proceeds from the Hong Kong listing and additional bank loans, which helps near-term liquidity
CCM Stock Risks: Concord Medical Services Holdings Ltd Investment Risks
- Complete absence of income statement data prevents profitability assessment
- No balance sheet data available to evaluate financial position and solvency
- Missing cash flow statements prevent evaluation of cash generation and capital allocation
- No insider activity in last 90 days suggests potential lack of confidence or limited trading window
- Extremely low data quality score indicates potential company delinquency in SEC reporting or data aggregation failure
- Recurring losses, negative operating cash flow, and management's disclosed going-concern uncertainty indicate fragile financial health
- Leverage is very high relative to revenue and cash generation, with large near-term obligations and negative working capital
- Revenue quality is weak, with 2024 sales declining sharply and network-business revenue under pressure
Key Metrics to Watch
- Revenue and net income when data becomes available
- Operating cash flow and free cash flow generation
- Debt levels and interest coverage ratios for financial stability assessment
- Operating cash flow and free cash burn
- Gross margin trajectory and revenue growth in the hospital business versus total borrowings/current liabilities
Concord Medical Services Holdings Ltd (CCM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CCM Profit Margin, ROE & Profitability Analysis
CCM vs Services Sector: How Concord Medical Services Holdings Ltd Compares
How Concord Medical Services Holdings Ltd compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Concord Medical Services Holdings Ltd Stock Overvalued? CCM Valuation Analysis 2026
Based on fundamental analysis, Concord Medical Services Holdings Ltd has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Concord Medical Services Holdings Ltd Balance Sheet: CCM Debt, Cash & Liquidity
CCM Revenue Growth, EPS Growth & YoY Performance
CCM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Concord Medical Services Holdings Ltd (CIK: 0001472072)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CCM
What is the AI rating for CCM?
Concord Medical Services Holdings Ltd (CCM) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (STRONG SELL) with 47% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CCM's key strengths?
Claude: . ChatGPT: First-half 2025 showed meaningful operating improvement, with gross loss narrowing sharply and loss attributable to shareholders falling versus the prior-year period. The company has a sizable asset base centered on hospitals and oncology infrastructure, which could support long-term strategic value if utilization improves.
What are the risks of investing in CCM?
Claude: Complete absence of income statement data prevents profitability assessment. No balance sheet data available to evaluate financial position and solvency. ChatGPT: Recurring losses, negative operating cash flow, and management's disclosed going-concern uncertainty indicate fragile financial health. Leverage is very high relative to revenue and cash generation, with large near-term obligations and negative working capital.
What is CCM's revenue and growth?
Concord Medical Services Holdings Ltd reported revenue of N/A.
Does CCM pay dividends?
Concord Medical Services Holdings Ltd does not currently pay dividends.
Where can I find CCM SEC filings?
Official SEC filings for Concord Medical Services Holdings Ltd (CIK: 0001472072) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CCM's EPS?
Concord Medical Services Holdings Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CCM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Concord Medical Services Holdings Ltd has a SELL rating with 47% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CCM stock overvalued or undervalued?
Valuation metrics for CCM: ROE of N/A (sector avg: 16%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy CCM stock in 2026?
Our dual AI analysis gives Concord Medical Services Holdings Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CCM's free cash flow?
Concord Medical Services Holdings Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does CCM compare to other Services stocks?
Vs Services sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 16%), current ratio N/A (avg: 1.5).